Disclaimers:

01. Compatible insulin types: Human and animal; Fast acting insulins (bolus); Rapid Acting Insulin Analogs; Regular Human Insulin; Basal insulins; Intermediate-acting, commonly: NPH/ Isophane; Long-acting, commonly: Glargine, detemir, degludec; Premixtures (e.g. 30/70).

02. In a user survey, 78% of respondents answered they would recommend InsuJet™ to others.

03. In a user survey, 40% of the respondents answered they noticed using less insulin.

04. Needle-Free Jet Injection of Rapid-Acting Insulin Improves Early Postprandial Glucose Control in Patients With Diabetes. Diabetes Care, October 2013.

05. Body mass index and the efficacy of needle-free jet injection for the administration of rapid-acting insulin analogs, a post hoc analysis. Diabetes, Obesity and Metabolism, July 2012.

06. Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology. Diabetes Care, August 2011

07. A Pilot Study to Examine the Tolerability and Device Preference in Type 1 Diabetes of Insulin Apart Administered by InsuJet™ Compared with Subcutaneous Injection. Diabetes Technology & Therapeutics, 2014.

08. See medical deck Cost Analysis - North America, 2022 available on the Partner page.

09. Calculated at 4 injections a day with a hypodermic needle. 4 injection a day, every day of the year, adds up to 1,460 needles a year saved from use.   

*. The InsuJet™ is calibrated for U-100 insulins

**. Needle gauge 26-27 is commonly used for subcutaneous injections and is around 0.40 - 0.45mm in diameter. The orifice of the InsuJet™ Nozzle is about 0.15mm in diameter which is much smaller than conventional needle gauges used for subcutaneous insulin injections.

***. https://pubmed.ncbi.nlm.nih.gov PMID:18820853